Sustained Elevation in Intraocular Pressure Associated With Intravitreal Bevacizumab Injections
Authors:
- Alan E. KimuraAKAlan E. Kimura
- Lisa J. WongLWLisa J. Wong
- David A. AmmarDADavid A. Ammar
- Marco A. MaycotteMMMarco A. Maycotte
- Naresh MandavaNMNaresh Mandava
- 1 May 2009
- journal article
- case report
- Published by SLACK, Inc. in Ophthalmic Surgery, Lasers and Imaging Retina
- Vol. 40 (3) , 293-295
Abstract
This retrospective case series reports sustained elevation of intraocular pressure (IOP) after single or repeated intravitreal injections of bevacizumab (Avastin; Genentech, San Francisco, CA) for wet age-related macular degeneration (AMD). All six cases experienced significant and sustained elevation in IOP after single or repeated intravitreal injections of bevacizumab. Initiation or advancement of IOP-lowering therapy was required in all cases. The results support the need for further studies investigating the incidence of this potential side effect and the need for close long-term surveillance of IOP after injection of bevacizumab, particularly in patients with glaucoma or suspected glaucoma. Future in vitro and in vivo studies are needed to better understand the reasons for this observed phenomenon. [Ophthalmic Surg Lasers Imaging 2009;40:293–295.]Keywords
This publication has 8 references indexed in Scilit:
- Short-term Intraocular Pressure Changes Immediately After Intravitreal Injections of Anti–Vascular Endothelial Growth Factor AgentsAmerican Journal of Ophthalmology, 2008
- Intraocular Pharmacokinetics of Bevacizumab After a Single Intravitreal Injection in HumansAmerican Journal of Ophthalmology, 2008
- Intravitreal bevacizumab (Avastin) causing acute glaucoma: an unreported complicationEye, 2007
- Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES)Graefe's Archive for Clinical and Experimental Ophthalmology, 2007
- The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwideBritish Journal of Ophthalmology, 2006
- SHORT-TERM SAFETY AND EFFICACY OF INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATIONRetina, 2006
- Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitroAngiogenesis, 2004
- Comparisons of the Intraocular Tissue Distribution, Pharmacokinetics, and Safety of 125I-Labeled Full-Length and Fab Antibodies in Rhesus Monkeys Following Intravitreal AdministrationToxicologic Pathology, 1999